COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS
First Claim
Patent Images
1. A composition comprising:
- cobicistat, or a pharmaceutically acceptable salt thereof; and
tenofovir alafenamide hemifumarate.
1 Assignment
0 Petitions
Accused Products
Abstract
The use of the hemifumarate form of {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and elvitegravir, and the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and darunavir, are disclosed.
-
Citations
32 Claims
-
1. A composition comprising:
- cobicistat, or a pharmaceutically acceptable salt thereof; and
tenofovir alafenamide hemifumarate. - View Dependent Claims (2, 3, 4, 12, 15)
- cobicistat, or a pharmaceutically acceptable salt thereof; and
- 5. A method of treating a viral infection in a human comprising coadministering cobicistat, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide hemifumarate, to the human.
- 6. A method of inhibiting activity of a retroviral reverse transcriptase comprising coadministering cobicistat, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide hemifumarate.
-
8-11. -11. (canceled)
- 13. A method of boosting an anti-viral effect of tenofovir alafenamide hemifumarate in a human comprising coadministering cobicistat, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide hemifumarate to the human.
- 16. A method of inhibiting Pgp-mediated intestinal secretion of tenofovir alafenamide hemifumarate in a human by coadministration of cobicistat, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide hemifumarate.
-
19. (canceled)
-
21. A composition comprising:
- (a) tenofovir alafenamide hemifumarate;
(b) cobicistat, or a pharmaceutically acceptable salt thereof;
(c) emtricitabine; and
(d) elvitegravir. - View Dependent Claims (23)
- (a) tenofovir alafenamide hemifumarate;
-
22. A composition comprising:
- (a) 3-40 mg tenofovir alafenamide hemifumarate;
(b) 50-500 mg cobicistat, or a pharmaceutically acceptable salt thereof;
(c) 50-500 mg emtricitabine; and
(d) 50-500 mg elvitegravir.
- (a) 3-40 mg tenofovir alafenamide hemifumarate;
-
24. A method of treating a viral infection in a human comprising coadministering (a) tenofovir alafenamide hemifumarate;
- (b) cobicistat, or a pharmaceutically acceptable salt thereof;
(c) emtricitabine; and
(d) elvitegravir to the human. - View Dependent Claims (25, 31)
- (b) cobicistat, or a pharmaceutically acceptable salt thereof;
-
26-30. -30. (canceled)
-
32. (canceled)
Specification